All Comments by
- Rakez Kayed on Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
- Suhail Rasool on San Diego: The Future of AD—Can We Vaccinate?
- Moustapha Cisse on Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.
- Lary Walker on Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS.
- Sergio Ferreira on Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation.
- Diana Frechilla on Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.
- Alexander Drzezga on APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.
- Pascale Lacor on Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.
- Lennart Mucke on Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.
- John Steele on Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.
- Ronit Sharon on A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain.
- Nikolaos K. Robakis on Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.
- Michael Nichols on San Diego: Flexible N-Termini Key to Aβ42 Oligomer Toxicity?
- Roxanne Ol on San Diego: TDP-43 Targets Loom Large—But Where’s the Bull’s Eye?
- Jens Pahnke on Paper Alert: In Vivo Human Data Shows Reduced Aβ Clearance in AD